Phase I/II open-label study of the biologic effects of the interleukin-2 immunocytokine EMD 273063 (hu14.18-IL2) in patients with metastatic malignant melanoma

Phase I/II open-label study of the biologic effects of the interleukin-2 immunocytokine EMD 273063 (hu14.18-IL2) in patients with metastatic malignant melanoma

<p>Abstract</p> <p>Background</p> <p>To explore the biological activity of EMD 273063 (hu14.18-IL2), a humanized anti-GD2 monoclonal antibody fused to interleukin-2 (IL2), in patients with unresectable, stage IV cutaneous melanoma as measured by induction of immune acti...

Full description

Bibliographic Details
Main Authors: Gillies Stephen D, Kovar Andreas, Gooding William, Whiteside Theresa L, Atkins Michael B, Kirkwood John M, Ribas Antoni, Kashala Oscar, Morse Michael A
Format: Article
Language:English
Published: BMC 2009-07-01
Series:Journal of Translational Medicine
Online Access:http://www.translational-medicine.com/content/7/1/68

Internet

http://www.translational-medicine.com/content/7/1/68

Similar Items